Anna L. Saborowski

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Journal: Frontiers in oncology
Published: June 02, 2026

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

Journal: ESMO gastrointestinal oncology
Published: May 22, 2026

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 28, 2026

Global biliary tract cancer genomics: From geographic patterns toward biological subtypes.

Global biliary tract cancer genomics: From geographic patterns toward biological subtypes.

Journal: Journal of hepatology
Published: April 19, 2026

Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

Journal: International journal of cancer
Published: March 23, 2026

From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.

From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.

Journal: Targeted oncology
Published: February 28, 2026

Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years.

Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years.

Journal: Targeted oncology
Published: February 27, 2026

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

Journal: International journal of cancer
Published: February 15, 2026

Perioperative approaches for patients with biliary tract cancer.

Perioperative approaches for patients with biliary tract cancer.

Journal: Nature reviews. Clinical oncology
Published: February 06, 2026

Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis.

Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis.

Journal: ESMO open
Published: January 05, 2026

The future of blood-based biomarkers in liver cancer.

The future of blood-based biomarkers in liver cancer.

Journal: Journal of hepatology
Published: December 20, 2025

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Journal: Nature reviews. Gastroenterology & hepatology
Published: October 31, 2025
Showing 1-12 of 91

Last Updated: 09/26/2026